$3.00
0.88% today
Nasdaq, Jul 18, 05:20 pm CET
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

NRX Pharmaceuticals Inc Stock price

$3.03
-0.31 9.28% 1M
-0.98 24.44% 6M
+0.83 37.73% YTD
+0.65 27.31% 1Y
-2.34 43.58% 3Y
-103.97 97.17% 5Y
-92.97 96.84% 10Y
-92.97 96.84% 20Y
Nasdaq, Closing price Thu, Jul 17 2025
+0.02 0.66%
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

Key metrics

Basic
Market capitalization
$59.1m
Enterprise Value
$62.0m
Net debt
$2.9m
Cash
$5.6m
Shares outstanding
17.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1.8
EV/Sales
- | 1.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-636.1%
Return on Equity
108.2%
ROCE
69.4%
ROIC
83.6%
Debt/Equity
-0.3
Financials (TTM | estimate)
Revenue
$0.0 | $33.2m
EBITDA
$-17.5m | -
EBIT
$-17.5m | $-3.3m
Net Income
$-24.1m | $-2.2m
Free Cash Flow
$-10.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
28.5% | -
EBIT
28.5% | 83.1%
Net Income
6.0% | 91.3%
Free Cash Flow
45.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -6.6%
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-0.6
Short interest
7.7%
Employees
-
Rev per Employee
-
Show more

Is NRX Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

NRX Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a NRX Pharmaceuticals Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a NRX Pharmaceuticals Inc forecast:

Buy
90%
Hold
10%

Financial data from NRX Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
4% 4%
-
- Research and Development Expense 5.26 5.26
54% 54%
-
-17 -17
28% 28%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
28% 28%
-
Net Profit -24 -24
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about NRX Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NRX Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
22 days ago
Cohen and Associates is a highly respected neuropsychiatry clinic in western Florida Cohen to serve as foundational clinic in the Sarasota - Bradenton area of Florida Acquisition expected to be immediately accretive to revenue and EBITDA MIAMI , June 26, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Ph...
Neutral
PRNewsWire
25 days ago
Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025 Application under CNPV program is accretive to already-filed Abbreviated New Drug Application (ANDA) for preservative-free ketamine, with proprietary formulation under priority review request Company has received and complied with FDA info...
Neutral
PRNewsWire
about one month ago
WILMINGTON, Del. , June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced a strategic investor relations partnership with astr par...
More NRX Pharmaceuticals Inc News

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Head office United States
CEO Jonathan Javitt
Founded 2017
Website www.nrxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today